ZBIO
Zenas BioPharma, Inc.
$19.64
+1.92%
2026-05-08
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
P/E Ratio
1.83
Forward P/E
-3.83
EPS (TTM)
$-8.44
ROE
-136.2%
Revenue Growth (YoY)
-100.0%
Profit Margin
0.0%
Debt/Equity
0.55
Price/Book
4.34
Market Cap
$1.20B
Avg Volume (10D)
555K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$29.55
60D Low
$17.20
Avg Volume
729K
Latest Close
$19.64
Get breakout alerts for ZBIO
Sign up for Breakout Scanner to receive daily notifications when ZBIO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Zenas BioPharma, Inc. (ZBIO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ZBIO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ZBIO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.